121 related articles for article (PubMed ID: 17115486)
1. Dicing with death : there's a good chance that the pills your doctor prescribed will do you no good and might even harm you.
Muir H
New Sci; 2006 Jul 29-Aug 4; 191(2562):38-41. PubMed ID: 17115486
[No Abstract] [Full Text] [Related]
2. Doctor explains why he blew the whistle.
Petersen M
N Y Times Web; 2003 Mar; ():C1, C2. PubMed ID: 12812161
[No Abstract] [Full Text] [Related]
3. Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder.
Chace MJ; Zhang F; Fullerton CA; Huskamp HA; Gilden D; Soumerai SB
J Clin Psychiatry; 2012 Nov; 73(11):1388-94. PubMed ID: 23146199
[TBL] [Abstract][Full Text] [Related]
4. Off-label prescribing explained. Why your doctor may recommend meds that aren't FDA-approved for your condition.
Johns Hopkins Med Lett Health After 50; 2011 Jun; 23(4):7. PubMed ID: 21702115
[No Abstract] [Full Text] [Related]
5. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.
Chen DT; Wynia MK; Moloney RM; Alexander GC
Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1094-100. PubMed ID: 19697444
[TBL] [Abstract][Full Text] [Related]
6. False Claims Act prosecution did not deter off-label drug use in the case of neurontin.
Kesselheim AS; Darby D; Studdert DM; Glynn R; Levin R; Avorn J
Health Aff (Millwood); 2011 Dec; 30(12):2318-27. PubMed ID: 22147859
[TBL] [Abstract][Full Text] [Related]
7. FDA approves gabapentin prodrug as restless legs treatment.
Thompson CA
Am J Health Syst Pharm; 2011 May; 68(10):862. PubMed ID: 21546634
[No Abstract] [Full Text] [Related]
8. Off-label or off-limits?
Ratner M; Gura T
Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
[No Abstract] [Full Text] [Related]
9. Court papers suggest scale of drug's use: lawsuit says doctors were paid endorsers.
Petersen M
N Y Times Web; 2003 May; ():C1, C2. PubMed ID: 12812176
[No Abstract] [Full Text] [Related]
10. The Neurontin legacy--marketing through misinformation and manipulation.
Landefeld CS; Steinman MA
N Engl J Med; 2009 Jan; 360(2):103-6. PubMed ID: 19129523
[No Abstract] [Full Text] [Related]
11. Confounding factors in off-label drug use.
Greenberg PE; Pike C; Sisitsky T
Health Aff (Millwood); 2012 Feb; 31(2):460; author reply 460. PubMed ID: 22323178
[No Abstract] [Full Text] [Related]
12. The top 50 prescription medications dispensed in pharmacies in 2001.
Wynn RL
Gen Dent; 2002; 50(5):400-4, 406. PubMed ID: 12448889
[No Abstract] [Full Text] [Related]
13. Pfizer pleads guilty, but drug sales continue to soar.
Lenzer J
BMJ; 2004 May; 328(7450):1217. PubMed ID: 15155480
[No Abstract] [Full Text] [Related]
14. Gabbing about gabapentin.
Nat Rev Drug Discov; 2003 Apr; 2(4):254. PubMed ID: 12680367
[No Abstract] [Full Text] [Related]
15. Drug maker to pay $430 million in fines, civil damages.
FDA Consum; 2004; 38(4):36-7. PubMed ID: 15346583
[TBL] [Abstract][Full Text] [Related]
16. Off-label marketing stirs a legal hornet's nest.
Guglielmo WJ
Med Econ; 2006 Oct; 83(19):47-9. PubMed ID: 17066854
[No Abstract] [Full Text] [Related]
17. Off-label prescribing among office-based physicians.
Radley DC; Finkelstein SN; Stafford RS
Arch Intern Med; 2006 May; 166(9):1021-6. PubMed ID: 16682577
[TBL] [Abstract][Full Text] [Related]
18. Results of drug trials can mystify doctors through omission: some professional groups demand public listing of all test outcomes.
Meier B
N Y Times Web; 2004 Jul; ():C1, C3. PubMed ID: 15290807
[No Abstract] [Full Text] [Related]
19. Pregnancy and pills. New research finds prescriptions may be safer than you think.
Schultz S
US News World Rep; 1999 Apr; 126(13):64-6. PubMed ID: 10351523
[No Abstract] [Full Text] [Related]
20. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
Poser S
Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
[No Abstract] [Full Text] [Related]
[Next] [New Search]
